Edition:
United States

Rxi Pharmaceuticals Corp (RXII.OQ)

RXII.OQ on NASDAQ Stock Exchange Capital Market

3.20USD
16 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.20
Open
$3.18
Day's High
$3.70
Day's Low
$3.14
Volume
26,199
Avg. Vol
11,194
52-wk High
$11.20
52-wk Low
$3.00

Latest Key Developments (Source: Significant Developments)

RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth
Tuesday, 16 Jan 2018 07:05am EST 

Jan 16 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS ANNOUNCES BUSINESS STRATEGY TO FOCUS ON IMMUNO-ONCOLOGY PROGRAMS TO ACCELERATE GROWTH.RXI PHARMACEUTICALS CORP - COMPANY TO "CAPITALIZE" ON PROPRIETARY SELF-DELIVERING RNAI PLATFORM (SD-RXRNA).RXI PHARMACEUTICALS CORP - 2018 BUSINESS STRATEGY INCLUDES DEVELOPING IMMUNO-ONCOLOGY TARGETS BEYOND CHECKPOINT INHIBITION, I.E. CELL DIFFERENTIATION.RXI PHARMACEUTICALS- RELATING TO OPERATIONAL REVIEW, RXI INTENDS TO PARTNER/OUT-LICENSE BOTH ITS DERMATOLOGY AND OPHTHALMOLOGY FRANCHISES.  Full Article

RXi Pharmaceuticals Announces Reverse Stock Split
Friday, 5 Jan 2018 12:45pm EST 

Jan 5 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS CORP - ANNOUNCED A REVERSE STOCK SPLIT OF ITS SHARES OF COMMON STOCK AT A RATIO OF 1-FOR-10.RXI PHARMACEUTICALS CORP - REVERSE STOCK SPLIT WILL BECOME EFFECTIVE AT 12:01 A.M. EASTERN TIME ON JANUARY 8, 2018.RXI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT.  Full Article

RXi Pharma Announces Meets Secondary Objective With RXI-109 For Dermal Scarring
Monday, 18 Dec 2017 07:05am EST 

Dec 18 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH RXI-109 FOR DERMAL SCARRING.RXI PHARMACEUTICALS CORP - RXI-109 MEETS SECONDARY OBJECTIVE AS IT WAS SHOWN TO BE SAFE AND WELL TOLERATED.RXI PHARMACEUTICALS CORP -RXI-109 STUDY SUCCESSFULLY MEETS PRIMARY EFFECTIVENESS OBJECTIVE WITH STATISTICALLY SIGNIFICANT OUTCOMES.RXI PHARMACEUTICALS - FULL STUDY RESULTS SHOW RXI-109 WAS SAFE, WELL TOLERATED FOR ALL DOSAGE GROUPS.  Full Article

RXi Pharma and Gustave Roussy have entered into a collaborative research agreement​
Monday, 13 Nov 2017 07:05am EST 

Nov 13 (Reuters) - Rxi Pharmaceuticals Corp :RXi Pharmaceuticals Corp - ‍co, Gustave Roussy announced that they have entered into a collaborative research agreement​.RXi Pharmaceuticals - ‍collaborative research agreement to evaluate potential of RXi's sd-rxRNA technology platform for use in cancer treatments​.  Full Article

RXi Pharmaceuticals reports Q3 2017 financial results and recent corporate highlights
Wednesday, 8 Nov 2017 07:05am EST 

Nov 8 (Reuters) - RXi Pharmaceuticals Corp ::Reports third quarter 2017 financial results and recent corporate highlights.At September 30, 2017, company had cash of $5.4 million, compared with $12.9 million at December 31, 2016​.Qtrly loss per share $0.11​.  Full Article

RXi Pharma announces completion of enrollment of phase 2 clinical trial
Wednesday, 6 Sep 2017 07:05am EDT 

Sept 6 (Reuters) - RXi Pharmaceuticals Corp ::RXi Pharmaceuticals announces completion of enrollment of phase 2 clinical trial with samcyprone for cutaneous warts.  Full Article

RXi Pharmaceuticals files for sale of up to 7.3 mln shares
Friday, 18 Aug 2017 05:44pm EDT 

Aug 18 (Reuters) - RXi Pharmaceuticals Corp ::RXi Pharmaceuticals Corp- files for sale of up to 7.3 million shares of common stock by Lincoln Park Capital Fund Llc - SEC filing‍​.  Full Article

RXi Pharmaceuticals Corp reports Q2 loss per share $0.11‍​
Thursday, 10 Aug 2017 07:05am EDT 

Aug 10 (Reuters) - RXi Pharmaceuticals Corp :RXi Pharmaceuticals reports second quarter 2017 financial results and recent corporate highlights.RXi Pharma - existing cash, potential proceeds available under equity facility with lpc should be sufficient to fund operations for at least next 12 months​.RXi Pharmaceuticals Corp qtrly loss per share $0.11‍​.  Full Article

RXi Pharmaceuticals enters into common stock purchase agreement for up to $15.0 million
Wednesday, 9 Aug 2017 07:05am EDT 

Aug 9 (Reuters) - RXi Pharmaceuticals Corp :RXi Pharmaceuticals enters into common stock purchase agreement for up to $15.0 million.RXi Pharmaceuticals Corp - ‍announced that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund, Llc​.  Full Article

RXI Pharma completes enrollment of Phase 1/2 trial with RXI-109
Wednesday, 21 Jun 2017 07:05am EDT 

June 21 (Reuters) - RXI Pharmaceuticals Corp ::RXI Pharmaceuticals announces completion of enrollment of Phase 1/2 clinical trial with RXI-109 for retinal scarring.RXI Pharmaceuticals Corp - RXI-109 has been well tolerated with no drug related issues occurring to date.  Full Article

BRIEF-RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth

* RXI PHARMACEUTICALS ANNOUNCES BUSINESS STRATEGY TO FOCUS ON IMMUNO-ONCOLOGY PROGRAMS TO ACCELERATE GROWTH